Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2025-12-25 @ 2:38 AM
NCT ID:
NCT00002434
Eligibility Criteria:
Inclusion Criteria
Concurrent Medication:
Allowed:
* Myelosuppressive or nephrotoxic agents at the discretion of the treating physician.
Patients must have:
* Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry.
* Serious intolerance and/or resistance to standard therapies (such as trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of therapy for the current episode of PCP, or a documented history of such intolerance during a prior episode.
* Consent of parent or guardian if less than 18 years of age.
NOTE:
* Pregnant women may enroll after the physician and patient have discussed the potential benefit versus risk.
Exclusion Criteria
Patients with the following prior conditions are excluded:
History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions due to trimetrexate glucuronate.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
2 Years
Study:
NCT00002434
Study Brief:
Protocol Section:
NCT00002434